Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an announcement.
Shanghai Fosun Pharmaceutical’s subsidiary, Fosun Adgenvax, has received approval from China’s National Medical Products Administration to conduct a Phase I clinical trial for its 24-valent pneumococcal polysaccharide conjugate vaccine. This development marks a significant step in the company’s efforts to advance its vaccine portfolio, leveraging its proprietary platform technology to address infectious diseases caused by various pneumococcal serotypes.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a leading company in the pharmaceutical industry, primarily engaged in the development and manufacturing of medical products. The company focuses on innovative drugs, diagnostic products, and medical devices, with a strong market presence in China and expanding global operations.
YTD Price Performance: 14.20%
Average Trading Volume: 5,824
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $8.35B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.